Table 3.
Ongoing clinical trials against SARS-CoV2 using MAPKinase Inhibitors.
| MAPK Inhibitor | Mechanism of Action | References | Current Status of Clinical Trials against SARS CoV-2 |
|---|---|---|---|
| Trametinib Selumetinib |
Inhibits MAPK/ERK—kinase family proteins viz. MEK1/2 inhibitor—Inhibits MAPK/ERK—kinase family Investigational (Phase III) MEK1/ERK1/2 inhibitor |
(72) (72) |
Ongoing Ongoing |
| Everolimus Miltefosine Teriflunamide Leflunomide |
Inhibits PI3K/Akt/mTOR Kinases—Akt/mTOR Inhibits viral block of cell stress response and apoptosis |
(73) | Ongoing |
| Dasatinib Imatinib Nilotinib |
Inhibition of actin motility Blocks ABL1 kinase. |
(73) (74) |
Ongoing |
| PD98059 SB308520 SP600125 |
MEK inhibitor p38 inhibitor JNK inhibitor *MOA: Inhibits SARS-CoV S protein-induced IL-8 Promoter activity using above MAPK cascade inhibitors |
(35) | – |
| Chloroquine (NCT04351724) Hydroxychlorquine (NCT04352933) |
Inhibits p38 MAPK activation and blocks viral replication | (70, 71) | Ongoing |
*
Mechanism of action.